Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined. METHODS: We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. RESULTS: After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). CONCLUSIONS: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intensive glucose control (A1C levels <7% in T2D and <7.5% in T1D) in several clinical trials was found to reduce the risk of incident albuminuria (A2) and DKD onset.70,78,90,406–410”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“Finally, in the UKPDS, wherein intensive treatment led to a mean end point A1C of 7.0%, hypoglycemia occurred in 1.8% of insulin-treated persons per year in the intensive group vs 0.7% of conventionally treated persons per year.407”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“However, because of the gaps in data and negative study results, uncertainty exists over the benefits of applying proven CVD therapy in the general population to the CKD population, especially in patients with advanced kidney disease.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Takayama F, 1998, Cell Mol Biol, 44, 1101
Cited by
Items 401–500 of 1,004
Lipoprotein metabolism in chronic renal insufficiency
Saland, J. M., & Ginsberg, H. N. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0467-5 · Cited by 87
Stroke in patients with chronic kidney disease…: How do we approach and manage it?
Nayak‐Rao, S., & Shenoy, M. P. (2017) · Indian Journal of Nephrology · doi:10.4103/0971-4065.202405 · Cited by 80
The association of lipid levels with mortality in patients on chronic peritoneal dialysis
Habib, A. N., Baird, B. C., Leypoldt, J. K., Cheung, A. K., & Goldfarb‐Rumyantzev, A. S. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl272 · Cited by 79
Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis
Shoji, T., Abe, T., Matsuo, H., Egusa, G., Yamasaki, Y., Kashihara, N., Shirai, K., & Kashiwagi, A. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10454 · Cited by 90
Drechsler, C., for the German Diabetes and Dialysis Study Investigators, Krane, V., Winkler, K., Dekker, F. W., & Wanner, C. (2009) · Kidney International · doi:10.1038/ki.2009.200 · Cited by 77
Self-citationHomoarginine, Heart Failure, and Sudden Cardiac Death in Haemodialysis Patients
Drechsler, C., Meinitzer, A., Pilz, S., Krane, V., Tomaschitz, A., Ritz, E., März, W., & Wanner, C. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr056 · Cited by 77
Self-citationCardiac Rhythm Disturbances in Hemodialysis Patients
Sacher, F., Jesel, L., Borni-Duval, C., Precigout, V. D., Lavainne, F., Bourdenx, J.-P., Haddj-Elmrabet, A., Seigneuric, B., Keller, A., Ott, J., et al. (2017) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2017.08.002 · Cited by 77
Reverse Epidemiology: A Confusing, Confounding, and Inaccurate Term
Levin, N. W., Handelman, G. J., Coresh, J., Port, F. K., & Kaysen, G. A. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00366.x · Cited by 80
Glycemic Control and the Risk of Death in 1,484 Patients Receiving Maintenance Hemodialysis
Shurraw, S., Majumdar, S. R., Thadhani, R., Wiebe, N., & Tonelli, M. A. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.12.038 · Cited by 80
Mechanisms for increased cardiovascular disease in chronic kidney dysfunction
Yamamoto, S., & Kon, V. (2009) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328327b360 · Cited by 82
An Update on Coronary Artery Disease and Chronic Kidney Disease
Afşar, B., Türkmen, K., Covic, A. C., & Kanbay, M. (2014) · International Journal of Nephrology · doi:10.1155/2014/767424 · Cited by 83
Visconti, L., Benvenga, S., Lacquaniti, A., Cernaro, V., Bruzzese, A., Conti, G., Buemi, M., & Santoro, D. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.08.002 · Cited by 82
Best Practice for Diabetic Patients on Hemodialysis 2012
Nakao, T., Inaba, M., Abe, M., Kaizu, K., Shima, K., Babazono, T., Tomo, T., Hirakata, H., Akizawa, T., & Japanese Society for Dialysis Therapy (2015) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12299 · Cited by 80
Benefits of statin therapy and compliance in high risk cardiovascular patients
Deedwania, P., & Lardizabal (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s9474 · Cited by 78
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease
Erickson, K. F., Japa, S., Owens, D. K., Chertow, G. M., Garber, A. M., & Goldhaber-Fiebert, J. D. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.034 · Cited by 74
Majithia, A., Bhatt, D. L., Friedman, A. N., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055560 · Cited by 74
Ischaemic stroke in incident dialysis patients
Sánchez-Perales, C., Vázquez, E., García-Cortes, M. J., Borrego, J., Polaina, M., Gutierrez, C. P., Lozano, C., & Liébana, A. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq220 · Cited by 74
Is the Declining Use of Long-Term Peritoneal Dialysis Justified by Outcome Data?
Khawar, O. S., Kalantar‐Zadeh, K., Lo, W. K., Johnson, D. W., & Mehrotra, R. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02550607 · Cited by 79
Low-density lipoprotein cholesterol lowering treatment: the current approach
Crîşmaru, I., Stoian, A. P., Bratu, O. G., Găman, M., Stănescu, A. M. A., Bacalbaşa, N., & Diaconu, C. C. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01275-x · Cited by 76
Rakhit, D. J., Zhang, X. H., Leano, R., Armstrong, K. A., Isbel, N. M., & Marwick, T. H. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.01.028 · Cited by 73
van den Hoek, H. L., Bos, W. J. W., de Boer, A., & van de Garde, E. M. W. (2011) · BMJ · doi:10.1136/bmj.d7281 · Cited by 78
Anemia as a risk factor for chronic kidney disease
Iseki, K., & Kohagura, K. (2007) · Kidney International · doi:10.1038/sj.ki.5002481 · Cited by 73
Wang, S., Cai, R., Yuan, Y., Varghese, Z., Moorhead, J. F., & Ruan, X. Z. (2017) · Scientific Reports · doi:10.1038/srep39982 · Cited by 79
Current trends in European renal epidemiology
Heaf, J. G. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfw150 · Cited by 79
Cardiac Imaging for Coronary Heart Disease Risk Stratification in Chronic Kidney Disease
Dilsizian, V., Gewirtz, H., Marwick, T. H., Kwong, R. Y. K., Raggi, P., Al-Mallah, M. H., & Herzog, C. A. (2020) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.05.035 · Cited by 72
Predialysis Nephrology Care of Older Patients Approaching End-stage Renal Disease
Winkelmayer, W. C. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.360 · Cited by 72
Shepherd, J., Kastelein, J. J. P., Bittner, V., Carmena, R., DEEDWANIA, P. C., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A. L., & WENGER, N. K. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.8.870 · Cited by 75
Risk Assessment for Sudden Cardiac Death in Dialysis Patients
Saravanan, P., & Davidson, N. C. (2010) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.110.937888 · Cited by 72
Causes and Consequences of Chronic Kidney Disease: Implications for Managed Health Care
Weiner, D. E. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.s3.1 · Cited by 92
LDL cholesterol in CKD—to treat or not to treat?
Massy, Z. A., & de Zeeuw, D. (2013) · Kidney International · doi:10.1038/ki.2013.181 · Cited by 77
Effects of statins on renal function
Agarwal, R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.110 · Cited by 71
Peev, V., Nayer, A., & Contreras, G. N. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000045 · Cited by 71
Statins for Treatment of Dyslipidemia in Chronic Kidney Disease
Shurraw, S., & Tonelli, M. A. (2006) · Peritoneal Dialysis International · doi:10.1177/089686080602600503 · Cited by 71
Svensson, M. H. S., Schmidt, E. B., Jørgensen, K. A., & Christensen, J. H. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn180 · Cited by 74
Does statins promote vascular calcification in chronic kidney disease?
Chen, Z., Qureshi, A. R., Parini, P., Hurt‐Camejo, E., Ripsweden, J., Brismar, T. B., Barany, P. F., Jaminon, A. M. G., Schurgers, L. J., Heimbürger, O., et al. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12718 · Cited by 73
Winkler, K., Wanner, C., Drechsler, C., Lilienthal, J., Marz, W., Krane, V., & for the German Diabetes and Dialysis Study Investigators (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn278 · Cited by 71
Self-citationLeft Ventricular Hypertrophy: Is Hyperphosphatemia among Dialysis Patients a Risk Factor?
Achinger, S. G., & Ayus, J. C. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080923 · Cited by 71
Willeit, P., Yeang, C., Moriarty, P. M., Tschiderer, L., Varvel, S. A., McConnell, J. P., & Tsimikas, S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016318 · Cited by 71
Kovesdy, C. P., & Anderson, J. E. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00335.x · Cited by 73
Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home
Jun, M., Jardine, M., Gray, N. A., Masterson, R., Kerr, P. G., Agar, J. W. M., Hawley, C. M., van Eps, C. L., Cass, A., Gallagher, M., et al. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.08.032 · Cited by 70
Is There a Role for Intradialytic Parenteral Nutrition? A Review of the Evidence
Dukkipati, R. B., Kalantar‐Zadeh, K., & Kopple, J. D. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.08.006 · Cited by 70
Chen, Y., Abbate, M., Tang, L., Cai, G., Gong, Z., Wei, R., Zhou, J., & Chen, X. (2013) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.062802 · Cited by 70
Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease
Radbill, B. D., Murphy, B. T., & LeRoith, D. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.12.1373 · Cited by 77
Thyroid Function, Cardiovascular Events, and Mortality in Diabetic Hemodialysis Patients
Drechsler, C., Schneider, A., Gutjahr-Lengsfeld, L., Kroiss, M., Carrero, J. J., Krane, V., Allolio, B., Wanner, C., & Fassnacht, M. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.009 · Cited by 70
Self-citationLipoproteins in chronic kidney disease: from bench to bedside
Speer, T., Ridker, P. M., von Eckardstein, A., Schunk, S. J., & Fliser, D. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1050 · Cited by 69
Giraldez, R. R., Giugliano, R. P., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Cannon, C. P., & Braunwald, E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.046 · Cited by 69
Review of Clinical Practice Guidelines for the Management of LDL-Related Risk
Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Dunn, S. P., & Urbina, E. M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.015 · Cited by 74
Patel, R. K., Jardine, A. G. M., Mark, P. B., Cunningham, A. F., Steedman, T., Powell, J. R., McQuarrie, E. P., Stevens, K. K., Dargie, H. J., & Jardine, A. G. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.12.033 · Cited by 69
Peripheral Arterial Disease: A Guide for Nephrologists
DeLoach, S. S., & Mohler, E. R. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04101206 · Cited by 74
Charytan, D. M., Foley, R. N., McCullough, P. A., Rogers, J., ZIMETBAUM, P. J., Herzog, C. A., & Tumlin, J. A. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09350915 · Cited by 69
Chang, T. I., Streja, E., Soohoo, M., Kim, T., Rhee, C. M., Kovesdy, C. P., Kashyap, M. L., Vaziri, N. D., Kalantar‐Zadeh, K., & Moradi, H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08730816 · Cited by 77
Cardiovascular Disease in Patients with End-Stage Renal Disease on Hemodialysis
Aoki, J., & Ikari, Y. (2017) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00051 · Cited by 74
Meta-Analysis of Biochemical and Patient-Level Effects of Calcimimetic Therapy
Strippoli, G. F., Palmer, S. C., Tong, A., Elder, G. J., Messa, P., & Craig, J. C. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.01.015 · Cited by 69
Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis
Genser, B., & März, W. (2006) · Clinical Research in Cardiology · doi:10.1007/s00392-006-0403-x · Cited by 68
Self-citationNakamura, N., Torii, S., Tsuchiya, H., Nakano, A., Oikawa, Y., Yajima, J., Nakamura, S., Nakano, M., Masuda, N., Ohta, H., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016595 · Cited by 69
Kraus, M. A., Kalra, P. A., Hunter, J. A., Menoyo, J., & Stankus, N. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315578654 · Cited by 68
Dyslipidemia of kidney disease
Attman, P., & Samuelsson, O. G. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832dd832 · Cited by 79
Chan, K. E., Ikizler, T. A., Gamboa, J. L., Yu, C., Hakim, R. M., & Brown, N. J. (2011) · Kidney International · doi:10.1038/ki.2011.228 · Cited by 68
C-Reactive Protein: A Family of Proteins to Regulate Cardiovascular Function
Schwedler, S. B., Filep, J. G., Galle, J., Wanner, C., & Potempa, L. A. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.028 · Cited by 74
Self-citationAlberton, M., Wu, P., Druyts, E., Briel, M., & Mills, E. J. (2012) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcr158 · Cited by 66
Cardiovascular risk and management in chronic kidney disease
Rucker, D., & Tonelli, M. A. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.42 · Cited by 75
Lehrich, R. W., Pun, P. H., Tanenbaum, N. D., Smith, S. R., & Middleton, J. P. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006040392 · Cited by 67
Lipid abnormalities in kidney disease and management strategies
Pandya, V., Rao, A., & Chaudhary, K. (2015) · World Journal of Nephrology · doi:10.5527/wjn.v4.i1.83 · Cited by 79
Coagulation Meets Calcification: The Vitamin K System
Krüger, T., Westenfeld, R., Schurgers, L. J., & Brandenburg, V. M. (2009) · The International Journal of Artificial Organs · doi:10.1177/039139880903200202 · Cited by 67
Kono, K., Fujii, H., Nakai, K., Goto, S., Shite, J., Hirata, K.-I., Fukagawa, M., & Nishi, S. (2012) · Kidney International · doi:10.1038/ki.2012.118 · Cited by 66
Suki, W. N. (2007) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2007.10.019 · Cited by 65
FGF-23: the rise of a novel cardiovascular risk marker in CKD
Heine, G. H., Seiler, S., & Fliser, D. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs259 · Cited by 72
Wagner, M., Alam, A., Zimmermann, J., Rauh, K., Koljaja-Batzner, A., Raff, U., Wanner, C., & Schramm, L. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00380111 · Cited by 64
Self-citationKwakernaak, A. J., Lambert, G. C., Slagman, M. C. J., Waanders, F., Laverman, G. D., Petrides, F., Dikkeschei, B. D., Navis, G. J., & Dullaart, R. P. F. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.11.009 · Cited by 65
Warfarin in haemodialysis patients with atrial fibrillation: what benefit?
Yang, F., Chou, D., Schweitzer, P., & Hanon, S. (2010) · Europace · doi:10.1093/europace/euq387 · Cited by 66
The Role of Deprescribing in Older Adults with Chronic Kidney Disease
Triantafylidis, L. K., Hawley, C. E., Perry, L., & Paik, J. M. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0593-8 · Cited by 70
2015 Korean Guidelines for Management of Dyslipidemia
Committee for Guidelines for Management of Dyslipidemia (2015) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2015.4.1.61 · Cited by 71
Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials
Chan, D. T., Irish, A. B., Dogra, G. K., & Watts, G. F. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.01.023 · Cited by 67
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 80
Stroke in Dialysis and Chronic Kidney Disease
Power, A. J. (2013) · Blood Purification · doi:10.1159/000356086 · Cited by 64
Kopecky, C., Genser, B., Drechsler, C., Krane, V., Kaltenecker, C. C., Hengstschläger, M., März, W., Wanner, C., Säemann, M. D., & Weichhart, T. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06560714 · Cited by 63
Self-citationBangalore, S., Maron, D. J., Fleg, J. L., O’Brien, S. M., Herzog, C. A., Stone, G. W., Mark, D. B., Spertus, J. A., Alexander, K. P., Sidhu, M. S., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.07.023 · Cited by 61
Sárközy, M., Kovács, Z. Z. A., Kovács, M. G., Gáspár, R., Szűcs, G., & László, A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01648 · Cited by 66
Uraemic Cardiomyopathy: A Review of Current Literature
Garikapati, K., Goh, D. S. L., Khanna, S., & Echampati, K. (2021) · Clinical Medicine Insights Cardiology · doi:10.1177/1179546821998347 · Cited by 63
The Interplay Between CKD, Sudden Cardiac Death, and Ventricular Arrhythmias
Pun, P. H. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.06.007 · Cited by 68
Shantouf, R. S., Budoff, M. J., Ahmadi, N., Tiano, J., Flores, F. R., & Kalantar‐Zadeh, K. (2007) · American Journal of Nephrology · doi:10.1159/000111061 · Cited by 68
Did 20 Years of Technological Innovations in Hemodialysis Contribute to Better Patient Outcomes?
Lameire, N., Biesen, W. V., & Vanholder, R. C. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04000609 · Cited by 63
Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients
Drechsler, C., Ritz, E., Tomaschitz, A., Pilz, S., Schönfeld, S., Blouin, K., Bidlingmaier, M., Hammer, F., Krane, V., März, W., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs361 · Cited by 63
Self-citationRodelo‐Haad, C., Santamaría, R., Muñoz-Castañeda, J. R., de Mier, M. V. P.-R., Martín‐Malo, A., & Rodríguez, M. (2019) · Toxins · doi:10.3390/toxins11030175 · Cited by 67
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.67 · Cited by 68
Nishimura, M., Tokoro, T., Nishida, M., Hashimoto, T., Kobayashi, H., Yamazaki, S., Imai, R., Okino, K., Iwamoto, N., Takahashi, H., et al. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.12.104 · Cited by 62
Delfino, V. D. A., Vianna, A. C. A., Mocelin, A. J., Barbosa, D. S., Mise, R. A., & Matsuo, T. (2007) · Nutrition · doi:10.1016/j.nut.2007.01.002 · Cited by 68
Sudden Death in Hemodialysis: An Update
Kanbay, M., Afşar, B., Goldsmith, D. J. A., & Covic, A. C. (2010) · Blood Purification · doi:10.1159/000320370 · Cited by 62
Sandoval, Y. B., Herzog, C. A., Love, S. A., Cao, J., Hu, Y., Wu, A. H. B., Gilbertson, D. T., Brunelli, S. M., Young, A., Ler, R., et al. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.251835 · Cited by 68
Mineral metabolism and cardiovascular disease in CKD
Fujii, H., & Joki, N. (2017) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1363-8 · Cited by 63
Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease
Molitch, M. E. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00780306 · Cited by 63
Impact of Comorbidities on Mortality in Managed Care Patients With CKD
Gullion, C. M., Keith, D. S., Nichols, G. A., & Smith, D. H. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.04.083 · Cited by 66
Endothelial dysfunction in chronic kidney disease: a clinical perspective
Cho, M. E., Brunt, V. E., Shiu, Y.-T., & Bunsawat, K. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00908.2024 · Cited by 61
Chen, Y., Ku, H., Zhao, L., Wheeler, D. C., Li, L.-C., Li, Q., Varghese, Z., Moorhead, J. F., Powis, S. H., Huang, A., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301301 · Cited by 61
Abbasi, M. A., Chertow, G. M., & Hall, Y. N. (2005) · PubMed · Cited by 61
Electrocardiography and Outcome in Patients with Diabetes Mellitus on Maintenance Hemodialysis
Krane, V., Heinrich, F., Meesmann, M., Olschewski, M., Lilienthal, J. D., Angermann, C., Störk, S., Bauersachs, J. K., Wanner, C., & Frantz, S. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02020408 · Cited by 61
Self-citationRole of Statins in Coronary Artery Disease
Lim, S. Y. (2013) · Chonnam Medical Journal · doi:10.4068/cmj.2013.49.1.1 · Cited by 58
Development and validation of cardiovascular risk scores for haemodialysis patients
Anker, S. D., Gillespie, I. A., Eckardt, K., Kronenberg, F., Richards, S., Drüeke, T. B., Stenvinkel, P., Pisoni, R. L., Robinson, B. M., Marcelli, D., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.151 · Cited by 66
HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients
Kopecky, C., Ebtehaj, S., Genser, B., Drechsler, C., Krane, V., Antlanger, M., Kovarik, J. J., Kaltenecker, C. C., Parvizi, M., Wanner, C., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030262 · Cited by 61
Self-citationKleber, M. E., Seppälä, I., Pilz, S., Hoffmann, M. M., Tomaschitz, A., Oksala, N., Raitoharju, E., Lyytikäinen, L., Mäkelä, K.-M., Laaksonen, R., et al. (2013) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000108 · Cited by 65
Self-citation
Metadata
- Authors
- Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E.
- Affiliations
- University of Würzburg (DE)
- Medical University of Graz (AT)
- University Medical Center Freiburg (DE)
- München Klinik Schwabing (DE)
- Pfizer (Germany) (DE)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-21
- Volume
- 353
- Issue
- 3
- Pages
- 238-248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110601215
- Cited by
- 2,614
- References
- 30
- Citations by year
- 2026: 74 · 2025: 51 · 2024: 66 · 2023: 76 · 2022: 90 · 2021: 92 · 2020: 97 · 2019: 110 · 2018: 96 · 2017: 104 · 2016: 110 · 2015: 132 · 2014: 153 · 2013: 162 · 2012: 185
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- atorvastatin, type 2 diabetes, hemodialysis, statins, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, LDL cholesterol, end-stage renal disease
- MeSH terms
- Atorvastatin, Aged, Cerebrovascular Disorders, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Diseases, Renal Dialysis, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Pyrroles, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.